^
Association details:
| Biomarker: | High HDAC6 score |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | rocilinostat (ACY-1215) (HDAC6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
645 - Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat
Published date:
03/10/2021
Excerpt:
...high HDAC6 scores. Based on these results, we designed a phase Ib clinical trial to evaluate the activity of ricolinostat plus nab-paclitaxel…. Expansion of our analysis to other tumor types identified multiple cohorts enriched in high HDAC6 score samples. These results suggest that the HDAC6 score may provide an effective, CLIA certified predictive biomarker of ricolinostat sensitivity in multiple human cancers.
Secondary therapy:
albumin-bound paclitaxel
